(Q51037023)

English

Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy.

scientific article published on 7 November 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25376846%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25376846%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Hodgkin lymphoma

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25376846%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Alessandra Romano

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25376846%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Annalisa Chiarenza

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25376846%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Giuseppe Alberto Palumbo

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25376846%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Nunziatina Laura Parrinello

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25376846%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Calogero Vetro

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25376846%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Amalia Figuera

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25376846%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Giovanna Motta

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25376846%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Massimo Ippolito

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25376846%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Ugo Consoli

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25376846%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Francesco Di Raimondo

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25376846%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

language of work or name

0 references

publication date

7 November 2014

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25376846%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

British Journal of Haematology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25376846%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

168

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25376846%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25376846%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

689-700

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25376846%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13198

21 January 2018

The prognostic significance of cellular subtypes in nodular sclerosing Hodgkin's disease: an analysis of 271 non-laparotomised cases (BNLI report no. 22).

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13198

21 January 2018

High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13198

21 January 2018

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13198

21 January 2018

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13198

21 January 2018

Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13198

21 January 2018

Macrophage, mast cell and T lymphocyte infiltrations are independent predictive biomarkers of primary refractoriness or early relapse in classical Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13198

21 January 2018

Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13198

21 January 2018

Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13198

21 January 2018

Coordinated regulation of myeloid cells by tumours

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13198

21 January 2018

Positron emission tomography scanning: a new paradigm for the management of Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13198

21 January 2018

Positron emission tomography/computed tomography surveillance in patients with lymphoma: a fox hunt?

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13198

21 January 2018

Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13198

21 January 2018

Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13198

21 January 2018

Standard therapies versus novel therapies in Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13198

21 January 2018

Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13198

21 January 2018

CD163 versus CD68 in tumor associated macrophages of classical Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13198

21 January 2018

Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13198

21 January 2018

Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13198

21 January 2018

Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13198

21 January 2018

Hodgkin's Lymphomas: A Tumor Recognized by Its Microenvironment

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13198

21 January 2018

Regulatory myeloid suppressor cells in health and disease

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13198

21 January 2018

Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13198

21 January 2018

Myeloid-derived suppressor cell heterogeneity and subset definition.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13198

21 January 2018

Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13198

21 January 2018

Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13198

21 January 2018

Early interim 2-(1)fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to peripheral blood lymphocyte/monocyte ratio at diagnosis in classical Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13198

21 January 2018

High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13198

21 January 2018

Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13198

21 January 2018

Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13198

21 January 2018

Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13198

21 January 2018

Tumor-associated macrophages and survival in classic Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13198

21 January 2018

Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13198

21 January 2018

Macrophages predict treatment outcome in Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13198

21 January 2018

History of myeloid-derived suppressor cells

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13198

21 January 2018

Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13198

21 January 2018

Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA-DR−/low Myeloid-Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13198

21 January 2018

Identifiers

10.1111/BJH.13198

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25376846%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25376846%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51037023&oldid=1520990154"